Back to search results

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Bruno Bockorny, MD)

  • Hospital Universitari Vall d'Hebron, Barcelona, Barcelona, Spain

    Contact: Study coordinator (María Vieito, MD)

  • ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

    Contact: Study coordinator (Marta Gil Martín, MD)

  • Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain

    Contact: Study coordinator (Rafael López López, MD) · Rafael.Lopez.Lopez@sergas.es · +34 981 950 512
    Contact: Study coordinator (Carolina García Martínez, SC) · cgarciamartinez.enf@gmail.com · +34 981 950 512

  • Hospital Universitario de Donostia, San Sebastián, Guipúzcoa, Spain

    Contact: Study coordinator (Ane Areizaga, MD)

  • Hospital 12 Octubre, Madrid, Madrid, Spain

    Contact: Study coordinator (Luis Paz-Ares, MD)

  • Hospital MD Anderson, Madrid, Madrid, Spain

    Contact: Study coordinator (Ricardo Cubedo, MD)

  • Clínica Universitaria de Navarra, Pamplona, Navarre, Spain

    Contact: Study coordinator (Mariano Ponz, MD)

  • Onkologikoa, San Sebastián, Spain

    Contact: Study coordinator (Ander Urriticoechea, MD)
Study leads

  • Ignacio García-Ribas, MD

    Study Director

    Oncomatryx Biopharm, S.L.

View source on ClinicalTrials.gov(opens in a new tab)